American Association for Cancer Research
Browse
00085472can112464-sup-figure_s1_pdf_5357k.pdf (5.23 MB)

Supplementary Figure 1 from Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion

Download (5.23 MB)
journal contribution
posted on 2023-03-30, 21:11 authored by A. Gregory Sorensen, Kyrre E. Emblem, Pavlina Polaskova, Dominique Jennings, Heisoog Kim, Marek Ancukiewicz, Meiyun Wang, Patrick Y. Wen, Percy Ivy, Tracy T. Batchelor, Rakesh K. Jain

PDF file - 5.2MB, Figure S1: Decreased Flow. Representative example of patient with flow decrease. (A) Anatomic MR imaging showing decrease in the contrast enhanced tumor area. (B) Flow maps showing decreasing flow. The blue ovals indicate region of tumor. (C) Histogram analysis of enhancing tumor showing decrease of flow compared to reference tissue.

History

ARTICLE ABSTRACT

The abnormal vasculature of the tumor microenvironment supports progression and resistance to treatment. Judicious application of antiangiogenic therapy may normalize the structure and function of the tumor vasculature, promoting improved blood perfusion. However, direct clinical evidence is lacking for improvements in blood perfusion after antiangiogenic therapy. In this study, we used MRI to assess tumor blood perfusion in 30 recurrent glioblastoma patients who were undergoing treatment with cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. Tumor blood perfusion increased durably for more than 1 month in 7 of 30 patients, in whom it was associated with longer survival. Together, our findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor perfusion and help improve patient survival. Cancer Res; 72(2); 402–7. ©2011 AACR.